Haemophilus influenzae Type b Conjugate and Hepatitis B (Recombinant)
Trade name: Comvax
Vaccineapproved
Approved
Oct 2, 1996
Haemophilus B and hepatitis B vaccine is a combination vaccine whose generic name is Haemophilus b conjugate and hepatitis B recombinant vaccine. It protects against the infectious diseases Haemophilus influenzae type B and hepatitis B. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Jun 1, 2000 (NCT00984295)
Timeline
Indications
Mechanism of action
- Hepatitis B virusANTAGONIST
Hepatitis B virus antagonist
Approval history
- approvedOct 2, 1996
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
Also known as
- comvax
- hepb-hib
- hib/hep b vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02584816 | Phase 3 | Nov 1, 2015 | PATH, Serum Institute of India Pvt. Ltd. |
| NCT00441012 | Phase 3 | Dec 1, 2006 | Merck |
| NCT00984295 | Phase 3 | Jun 1, 2000 | Merck |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 1 | 2000 |
| PATH | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Serum Institute of India Pvt. Ltd. | For profit | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1